Blood cell changes may predict pancreatic cancer survival
NCT ID NCT07329920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 300 people with pancreatic cancer to see if changes in a specific type of tumor cell in the blood (called mesenchymal circulating tumor cells) could predict how well they respond to treatment and how long they live. Researchers tracked these cells over time in patients receiving chemotherapy before surgery. The goal was to find a simple blood test that helps doctors personalize treatment and predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRCULATING TUMOR CELLS (CTCS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital of Naval Medical UniversityUniversity
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes